Second-Generation Antidepressants for Treating Adult Depression—An Update
Specific Comparative Harms of Second-Generation Antidepressants for Adults With MDD (3 of 3)
When compared with most selective serotonin reuptake inhibitors, there was high-strength evidence that higher discontinuation rates due to adverse effects were seen with duloxetine (67% higher risk) and venlafaxine (40% higher risk). There was also high-strength evidence that venlafaxine had lower discontinuation rates due to lack of efficacy (35% lower risk).
The highest rates of withdrawal symptoms (headache, dizziness, light-headedness, nausea, and anxiety) were reported after discontinuation of paroxetine or venlafaxine, and fluoxetine had the lowest rate of withdrawal symptoms (moderate-strength evidence).
- Gartlehner G, Hansen RA, Morgan LC, et al. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. Comparative Effectiveness Review No. 46 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; December 2011. AHRQ Publication No. 12-EHC012-EF. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.
Your slide tray is being processed.